These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 17641541)

  • 1. A dose escalation study of gemcitabine plus pemetrexed administered biweekly in patients with solid tumors.
    Kalykaki A; Vamvakas L; Agelaki S; Kalbakis K; Vardakis N; Sfakiotaki G; Ignatiadis M; Saridaki Z; Karampeazis A; Mavroudis D; Georgoulias V
    Oncology; 2006; 71(3-4):197-203. PubMed ID: 17641541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors.
    Yuan Y; Cohen DJ; Love E; Yaw M; Levinson B; Nicol SJ; Hochster HS
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):371-8. PubMed ID: 20978761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I trial of pemetrexed plus gemcitabine given biweekly with B-vitamin support in solid tumor malignancies or advanced epithelial ovarian cancer.
    Hensley ML; Larkin J; Fury M; Gerst S; Tai DF; Sabbatini P; Konner J; Orlando M; Goss TL; Aghajanian CA
    Clin Cancer Res; 2008 Oct; 14(19):6310-6. PubMed ID: 18829514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors.
    Dy GK; Suri A; Reid JM; Sloan JA; Pitot HC; Alberts SR; Goldberg RM; Atherton PJ; Hanson LJ; Burch PA; Rubin J; Erlichman C; Adjei AA
    Cancer Chemother Pharmacol; 2005 Jun; 55(6):522-30. PubMed ID: 15754203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of biweekly pemetrexed and gemcitabine in patients with previously untreated advanced non-small cell lung cancer.
    Spigel DR; Hainsworth JD; Barton JH; Patton JF; Zubkus JD; Simons L; Griner P; Burris HA; Greco FA
    J Thorac Oncol; 2010 Jun; 5(6):841-5. PubMed ID: 20421819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer.
    Chow LQ; Blais N; Jonker DJ; Laurie SA; Diab SG; Canil C; McWilliam M; Thall A; Ruiz-Garcia A; Zhang K; Tye L; Chao RC; Camidge DR
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):709-22. PubMed ID: 21989766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer.
    Kotsakis A; Agelaki S; Vardakis N; Stathopoulos G; Vamvakas L; Kalykaki A; Kentepozidis N; Kontopodis E; Sfakiotaki G; Mavroudis D; Georgoulias V
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):415-22. PubMed ID: 21069335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium.
    von der Maase H; Lehmann J; Gravis G; Joensuu H; Geertsen PF; Gough J; Chen G; Kania M
    Ann Oncol; 2006 Oct; 17(10):1533-8. PubMed ID: 16873433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase-I-study of four different schedules of pemetrexed, gemcitabine and cisplatin in patients with locally advanced or metastatic solid tumours.
    Hanauske AR; Endler C; Graefe T; Fleeth J; von Scheel J; Lüdtke FE; Müller-Hagen S; Depenbrock H; Ohnmacht U; Bolling C
    Eur J Cancer; 2008 Nov; 44(16):2444-52. PubMed ID: 18804996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A dose escalation and pharmacokinetic study of the biweekly administration of paclitaxel, gemcitabine and oxaliplatin in patients with advanced solid tumors.
    Saridaki Z; Pappas P; Souglakos J; Nikolaidou M; Vardakis N; Kotsakis A; Marselos M; Georgoulias V; Mavroudis D
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):121-8. PubMed ID: 19415279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors.
    Adjei AA; Erlichman C; Sloan JA; Reid JM; Pitot HC; Goldberg RM; Peethambaram P; Atherton P; Hanson LJ; Alberts SR; Jett J
    J Clin Oncol; 2000 Apr; 18(8):1748-57. PubMed ID: 10764436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pemetrexed and gemcitabine for biliary tract and gallbladder carcinomas: a North Central Cancer Treatment Group (NCCTG) phase I and II Trial, N9943.
    Alberts SR; Sande JR; Foster NR; Quevedo FJ; McWilliams RR; Kugler JW; Fitch TR; Jaslowski AJ
    J Gastrointest Cancer; 2007; 38(2-4):87-94. PubMed ID: 19023677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemcitabine combined with either pemetrexed or paclitaxel in the treatment of advanced non-small cell lung cancer: a randomized phase II SICOG trial.
    Comella P; Chiuri VE; De Cataldis G; Filippelli G; Maiorino L; Vessia G; Cioffi R; Mancarella S; Putzu C; Greco E; Palmeri L; Costanzo R; Avallone A; Franco L
    Lung Cancer; 2010 Apr; 68(1):94-8. PubMed ID: 19545929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors.
    Infante JR; Novello S; Ma WW; Dy GK; Bendell JC; Huff A; Wang Q; Suttle AB; Allen R; Xu CF; Ottesen LH; Burris HA; Adjei AA
    Invest New Drugs; 2013 Aug; 31(4):927-36. PubMed ID: 23179337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of biweekly pemetrexed and gemcitabine in patients with metastatic breast cancer.
    Dent SF; Gertler S; Verma S; Segal R; Young V; Goel R; Keller O; Canil C; Iscoe N
    Cancer Chemother Pharmacol; 2010 Feb; 65(3):557-61. PubMed ID: 19593565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial.
    Simon GR; Verschraegen CF; Jänne PA; Langer CJ; Dowlati A; Gadgeel SM; Kelly K; Kalemkerian GP; Traynor AM; Peng G; Gill J; Obasaju CK; Kindler HL
    J Clin Oncol; 2008 Jul; 26(21):3567-72. PubMed ID: 18640937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pemetrexed plus platinum or gemcitabine plus platinum for advanced non-small cell lung cancer: final survival analysis from a multicentre randomized phase II trial in the East Asia region and a meta-analysis.
    Zhang X; Lu J; Xu J; Li H; Wang J; Qin Y; Ma P; Wei L; He J
    Respirology; 2013 Jan; 18(1):131-9. PubMed ID: 22882698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II trial of pemetrexed and gemcitabine in patients with metastatic breast cancer who have received prior taxane therapy.
    Pippen J; Elias AD; Neubauer M; Stokoe C; Vaughn LG; Wang Y; Orlando M; Shonukan O; Muscato J; O'Shaughnessy JA; Gralow J
    Clin Breast Cancer; 2010 Apr; 10(2):148-53. PubMed ID: 20299319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A dose escalation study of biweekly oral vinorelbine and gemcitabine in patients with solid tumors.
    Karampeazis A; Vamvakas L; Agelaki S; Kentepozidis N; Papadimitraki E; Gioulbasanis I; Vardakis N; Ignatiadis M; Mavroudis D; Georgoulias V
    Oncology; 2006; 71(5-6):347-53. PubMed ID: 17785992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of a 3-drug regimen of gemcitabine/cisplatin/pemetrexed in patients with metastatic transitional cell carcinoma of the urothelium.
    Hutson TE; Vukelja S; Atienza D; Awasthi S; Delaune R; Deutsch M; Dien PY; Gregory TF; Kolodziej MJ; Muscato JJ; Raju RN; Ruxer RL; Mull S; Ilegbodu D; Hood K; Nicol S; Berry W
    Invest New Drugs; 2008 Apr; 26(2):151-8. PubMed ID: 18236006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.